Connect with us

Technology

Infosys Topaz Unveils Responsible AI Suite of Offerings, to help Enterprises Navigate the Regulatory and Ethical Complexities of AI-powered Transformation

Published

on

Responsible AI (RAI) Office will serve as the custodian of ethical use of AI and ensure solutions align with emerging guardrails for AI across geographies

BENGALURU, India, Feb. 27, 2024 /PRNewswire/ — Infosys (NSE: INFY) (BSE: INFY) (NYSE: INFY), a global leader in next-generation digital services and consulting, today announced the launch of its Responsible AI Suite, a part of Infosys Topaz, an AI-first set of services, solutions, and platforms using generative AI.­­­

The rise of powerful generative AI systems in the past year has raised several concerns and conversations around the ethical dimensions of AI. According to the Infosys Generative AI Radar, by Infosys Knowledge Institute, enterprises worldwide are identifying data privacy, security, ethics, and bias as the primary challenges in their pursuit of innovation with AI. The Responsible AI Suite is designed to help enterprises balance innovation with ethical considerations, such bias and privacy prevention, and maximize their return on investments.

Infosys Topaz Responsible AI Suite is a set of 10+ offerings built around the Scan, Shield, and Steer framework. The framework aims to monitor and protect AI models and systems from risks and threats, while enabling businesses to apply AI responsibly. The offerings, across the framework, include a combination of accelerators and solutions designed to drive responsible AI adoption across enterprises.

Scan: Includes solutions to help identify the overall AI risk posture, legal obligations, vulnerabilities, and generate a single source of truth for compliance status of all AI projects. For example, the Infosys Topaz RAI Watchtower is used to monitor upcoming threats, vulnerabilities, and legal obligations.

Shield: These solutions focus on building technical guardrails, checks, and accelerators that are responsible by design across the AI lifecycle. It also consists of specialized solutions for AI security. For example, the Infosys Topaz Gen AI Guardrails help enforce the safe use of Gen AI by moderating input prompts and output for multiple risks.

Steer: These advisory and consulting services support strong and efficient AI governance for innovation. Offerings include AI strategy formulation, legal consultation, and contract reviews.

Infosys Topaz Responsible AI Suite will be amplified by an ecosystem of technology partners and think tanks via the Responsible AI Coalition. The Responsible AI Coalition will bring together startups, cloud service providers, and technology partners to further the common goal of advancing responsible AI. It will also lead a special working group of noted academicians, influencers, policymakers, and industry leaders to aid in shaping solutions that help set new industry standards in the responsible AI space.

Phil Fersht, CEO and Chief Analyst, HFS Research, said, “With the challenges of Responsible AI currently forcing many enterprises to slow their progress towards achieving scaled value with AI, smart offerings such as Infosys Topaz’s Responsible AI suite can clear the path to help them accelerate their critical AI initiatives.”

The suite of offerings is complemented by Infosys Topaz RAI office. This ensures that the offerings deliver solutions that ably navigate the shifting landscape of complex technical, policy, and governance challenges related to adopting AI responsibly across business functions. The office of RAI is also responsible for looking into different facets of ethical aspects of AI like transparency, fairness, privacy, security and compliance. The Office constitutes a centralized body for streamlining AI governance, formulating AI risk strategy, and maintaining standards, policies, and guidelines. It will also ensure adherence to responsible-by-design principles and standards throughout the AI development lifecycle, facilitating safe use of AI across organizations.

Commenting on the launch, Balakrishna D. R. (Bali), Executive Vice President, Global Services Head, AI and Industry Verticals, Infosys, said, “Responsible and ethical AI deployment is a business imperative as technology evolves. At Infosys, we recognize the critical need for fostering responsible AI and not merely as a set of principles but as actionable steps. Infosys Topaz Responsible AI Suite is a significant stride in helping our clients better manage their AI-first journey. Together with the Infosys RAI office, we affirm our commitment to advancing the ethos of responsible AI, providing enterprises with the necessary tools and expertise for ethical AI implementation.”

About Infosys

Infosys is a global leader in next-generation digital services and consulting. Over 300,000 of our people work to amplify human potential and create the next opportunity for people, businesses and communities. We enable clients in more than 56 countries to navigate their digital transformation. With over four decades of experience in managing the systems and workings of global enterprises, we expertly steer clients, as they navigate their digital transformation powered by cloud and AI. We enable them with an AI-first core, empower the business with agile digital at scale and drive continuous improvement with always-on learning through the transfer of digital skills, expertise, and ideas from our innovation ecosystem. We are deeply committed to being a well-governed, environmentally sustainable organization where diverse talent thrives in an inclusive workplace.

Visit www.infosys.com to see how Infosys (NSE, BSE, NYSE: INFY) can help your enterprise navigate your next.

Safe Harbor

Certain statements in this release concerning our future growth prospects, or our future financial or operating performance, are forward-looking statements intended to qualify for the ‘safe harbor’ under the Private Securities Litigation Reform Act of 1995, which involve a number of risks and uncertainties that could cause actual results or outcomes to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding the execution of our business strategy, our ability to attract and retain personnel, our transition to hybrid work model, economic uncertainties, technological innovations such as Generative AI, the complex and evolving regulatory landscape including immigration regulation changes, our ESG vision, our capital allocation policy and expectations concerning our market position, future operations, margins, profitability, liquidity, capital resources, our corporate actions including acquisitions, and cybersecurity matters. Important factors that may cause actual results or outcomes to differ from those implied by the forward-looking statements are discussed in more detail in our US Securities and Exchange Commission filings including our Annual Report on Form 20-F for the fiscal year ended March 31, 2023. These filings are available at www.sec.gov. Infosys may, from time to time, make additional written and oral forward-looking statements, including statements contained in the Company’s filings with the Securities and Exchange Commission and our reports to shareholders. The Company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the Company unless it is required by law.

Logo: https://mma.prnewswire.com/media/633365/Infosys_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/infosys-topaz-unveils-responsible-ai-suite-of-offerings-to-help-enterprises-navigate-the-regulatory-and-ethical-complexities-of-ai-powered-transformation-302072355.html

SOURCE Infosys

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Weibo Corporation to Report First Quarter 2026 Financial Results on May 28, 2026

Published

on

By

BEIJING, April 27, 2026 /PRNewswire/ — Weibo Corporation (NASDAQ: WB and HKEX: 9898), a leading social media for people to create, share and discover content, will announce its unaudited financial results for the first quarter 2026 before the U.S. market opens on Thursday, May 28, 2026. Following the announcement, Weibo’s management team will host a conference call from 7 AM – 8 AM Eastern Time on May 28, 2026 (or 7 PM – 8 PM Beijing Time on May 28, 2026) to present an overview of the Company’s financial performance and business operations.

Participants who wish to dial in to the teleconference must register through the below public participant link. Dial in and instruction will be in the confirmation email upon registering.

Participants Registration Link: https://register-conf.media-server.com/register/BIb549b1f6935046d98b52a0fe61be918e

Additionally, a live and archived webcast of this conference call will be available at http://ir.weibo.com.

About Weibo Corporation

Weibo is a leading social media for people to create, share and discover content online. Weibo combines the means of public self-expression in real time with a powerful platform for social interaction, content aggregation and content distribution. Any user can create and post a feed and attach multi-media and long-form content. User relationships on Weibo may be asymmetric; any user can follow any other user and add comments to a feed while reposting. This simple, asymmetric and distributed nature of Weibo allows an original feed to become a live viral conversation stream.

Weibo enables its advertising and marketing customers to promote their brands, products and services to users. Weibo offers a wide range of advertising and marketing solutions to companies of all sizes. The Company generates a substantial majority of its revenues from the sale of advertising and marketing services, including the sale of social display advertisement and promoted marketing offerings. Designed with a “mobile first” philosophy, Weibo displays content in a simple information feed format and offers native advertisement that conform to the information feed on our platform. To support the mobile format, we have developed and continuously refining our social interest graph recommendation engine, which enables our customers to perform people marketing and target audiences based on user demographics, social relationships, interests and behaviors, to achieve greater relevance, engagement and marketing effectiveness

Contact:
Investor Relations
Weibo Corporation
Phone: +86 10 5898-3336
Email: ir@staff.weibo.com 

View original content:https://www.prnewswire.com/news-releases/weibo-corporation-to-report-first-quarter-2026-financial-results-on-may-28-2026-302754018.html

SOURCE Weibo Corporation

Continue Reading

Technology

Perceptive eClinical Launches Technology-Enabled Clinical Supply Consultancy in Alliance with Trialzen

Published

on

By

Expert-led clinical supply strategy powered by advanced planning and analytics technologies.

NOTTINGHAM, England and LASNE, Belgium, April 27, 2026 /PRNewswire/ — Perceptive eClinical, a leading provider of interactive response technology (IRT) and eClinical solutions, and Trialzen, an expert-led Forecasting and Supply Technology company, today announced an alliance supporting Perceptive eClinical in the launch of its Clinical Intelligence Consultancy Service, Perceptive Clinical Intelligence. This transforms its long–standing clinical supply expertise into a fully integrated, expert–led service spanning the entire clinical trial lifecycle and enabled by Trialzen’s advanced clinical supply planning technologies.

Perceptive Clinical Intelligence combines Perceptive’s deep expertise in randomization and clinical supply optimization with data-driven, technology enabled mathematical optimization, simulation, and forecasting to support smarter planning across the trial lifecycle. This integrated offering helps sponsors design, stress test, and manage clinical supply strategies with greater confidence and operational control. By formalizing its in-house expertise and therapeutic experience, Perceptive unifies randomization, trial supply management technologies and clinical supply consulting to enable more informed, scalable, and lower risk supply decision making.

“Clinical trial supply decisions are too critical to rely on tools alone,” said Malcolm Morrissey, Head of Perceptive Clinical Intelligence. “While supply discussions often focus on stock levels and overage, the real risk is patient impact. Supply availability determines whether visits happen, treatment is delivered on time, and sites can operate with confidence. Effective supply management means looking beyond IP numbers to understand patient continuity and visit level risk across the entire trial.”

Industry benchmarks show that approximately 50% of Clinical Finished Goods (CFG) manufactured for clinical trials are never administered to patients, representing hundreds of millions of dollars in wasted drug supply each year1.

“Setting up Perceptive Clinical Intelligence reflects the next step in Perceptive’s evolution, combining deep clinical supply and randomization expertise with data–driven technology to enable smarter supply planning, and increased supply confidence, and continuity across the trial lifecycle,” said Shaun Hopgood, Chief Operating Officer at Perceptive eClinical.

Perceptive eClinical and Trialzen have each delivered proven results for sponsors, with real–world engagements generating savings exceeding $1 million and materially reducing supply overage.

A Technology Enabled, Expert-Led Approach

Delivered by Perceptive’s in–house specialists, the consultancy is built on 30 years of experience supporting biotech and large pharma across randomization and clinical supply management. It combines Perceptive’s proven supply–modelling expertise with Trialzen’s advanced calculation and simulation engine, fully integrated into Perceptive’s next–generation platform, Clinphone Pro.

Anchored in deep oncology expertise, where global scale, complex dosing, and multi–layered supply chains increase planning risk, the consultancy also draws on experience across Endocrinology and Metabolism, and Infectious Diseases, and supports emerging areas such as Precision and Nuclear Medicine, and Cell and Gene Therapies. 

Reflecting on this alliance and its objectives, Cedric Druck, CEO and Co–Founder of Trialzen, commented: “Trialzen was built by clinical supply experts who spent years watching planning decisions get made on spreadsheets and gut feel, then handed off to execution systems with no feedback loop. This collaboration with Perceptive closes that gap. By integrating our forecasting and simulation capabilities directly with their IRT platform, we enable sponsors to move from scenario planning to operational action in a single environment, with full transparency at every step.”

At the heart of this alliance is a shared belief that clinical supply planning and execution should live in one connected environment. “Together, Perceptive and Trialzen are working toward a unified way of operating, where strategic decisions and day–to–day execution come together, enabling greater visibility, smarter scenarios, and more confident supply decisions from manufacturing through to patient dosing”. said Tony Street, Senior Vice President Strategy at Trialzen.

Clients benefit from:

Faster study start-up and smoother amendments through early supply optimizationHigher quality supply decisions driven by expert oversight and data backed insightGreater confidence through strategic expert consultancy for complex trialsMid-study forecast adjustments and up-to-date quantitative support for key decisions

About Perceptive eClinical

Perceptive eClinical is a trusted leader in delivering advanced trial capabilities. With over 30 years of proven Interactive Response Technology (IRT) and supply management expertise, more than 500 regulatory approvals and support for three million patients worldwide, we deliver reliability, security and precision. This is reflected in our consistently high customer satisfaction score of 4.5 out of 5 over the past three years. Our future-proof IRT solution, Clinphone Pro, helps sponsors manage the speed, complexity and personalization of modern clinical trials. Built for flexibility and seamless integration, it supports smarter, more efficient studies across all phases and therapeutic areas. In 2025, Perceptive eClinical was recognized as a leader in Everest Group’s PEAK Matrix® Assessment for RTSM Solutions, affirming our commitment to innovation, global delivery excellence and measurable value for sponsors and CROs.

About Trialzen

Trialzen is a technology company built by industry experts specializing in clinical trial supply forecasting and planning. Its Forecast & Planning Solution (FPS) is a purpose-built SaaS platform that enables sponsors and CROs to model, simulate, and optimize clinical supply strategies across the full trial lifecycle. Built by clinical supply experts, Trialzen combines advanced mathematical modelling and analytics with a transparent, user-friendly interface, allowing teams to evaluate scenarios, anticipate risk, and make informed supply decisions with speed and confidence. 

Sources

McKinsey & Company, Clinical Supply Chains insights

Media Contact: Zara Broadfield, Marketing Director Perceptive eClinical, zara.broadfield@perceptive.com 

Logo – https://mma.prnewswire.com/media/2965426/Perceptive_eClinical.jpg
Logo – https://mma.prnewswire.com/media/2965427/5936695/Trialzen.jpg

 

 

View original content:https://www.prnewswire.co.uk/news-releases/perceptive-eclinical-launches-technologyenabled-clinical-supply-consultancy-in-alliance-with-trialzen-302754074.html

Continue Reading

Technology

Mouser Electronics New Product Insider: Over 9,000 New Parts Added in First Quarter of 2026

Published

on

By

SHANGHAI, April 27, 2026 /PRNewswire/ — As an authorized distributor, Mouser Electronics, Inc. is focused on the rapid introduction of new products and technologies, giving customers an edge and helping speed time to market. Over 1,200 semiconductor and electronic component manufacturer brands count on Mouser to help them introduce their products into the global marketplace. Mouser’s customers can expect 100% certified, genuine products that are fully traceable from each manufacturer.

Last quarter, Mouser launched more than 9,000 part numbers ready for shipment. Some of the products introduced by Mouser from January through March 2026 include:

STMicroelectronics STM32C5 Arm® Cortex®-M33 Microcontrollers
The STM32C5 microcontrollers (MCUs) from STMicroelectronics are specifically designed to boost the performance of billions of tiny smart devices across factories, homes, cities, and infrastructure while meeting stringent cost, size, and power constraints. Based on ST’s proprietary 40 nm manufacturing process, the STM32C5 MCUs can run tasks noticeably faster than many entry-level chips currently in use. This gives products more room to include features such as improved sensing, smoother control, and enhanced user experiences while keeping dynamic power consumption low. The MCUs also integrate security features that help safeguard products against tampering and cyber risks.EDATEC ED-CM0NANO Single-Board Computer
The ED-CM0NANO is a single-board computer (SBC) from EDATEC, based on the Raspberry Pi Compute Module Zero (CM0). The ED-CM0NANO features a quad-core Arm Cortex-A53 processor running at up to 1 GHz, a Broadcom VideoCore-IV graphics processor, and a wide range of connectivity options. Optional Wi-Fi® support with an external antenna enables wireless connectivity, while integrated real-time clock (RTC) and watchdog timer enhance system reliability. These features make the ED-CM0NANO ideal for industrial control systems and Internet of Things (IoT) applications.Sensata Technologies MGD Resonix™ Refrigerant Leak Sensor
The MGD Resonix™ sensor from Sensata delivers high accuracy and fast response times in a compact module that fits into the smallest heating, ventilation, air conditioning (HVAC), and refrigeration equipment. The MGD series offers superior resistance to overexposure and poisoning, as well as to high temperatures (working temperatures up to 105 °C) and humidity. These devices also have a service life of more than 15 years with no need for calibration, making them the ideal leak-detection component for A2L HVAC and refrigeration systems.u-blox ANN-MB3 Triple-Band GNSS Antenna
The ANN-MB3 from u-blox is a best-in-class L1/L2/L5 triple-band RTK real-time kinematic (RTK) solution ideal for the F20 high-precision GNSS. Optimized for seamless integration, the ANN-MB3 antenna delivers exceptional performance with a robust design. The antenna’s compact (62 × 80 × 25.5 mm) form factor and flexible installation options enable the adoption of high-precision positioning technologies across industrial, automotive, and robotics applications.

To see more of the New Product Insider highlights, go to https://info.mouser.com/new_products/.

For more Mouser news and our latest new product introductions, visit https://www.mouser.com/newsroom/.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/mouser-electronics-new-product-insider-over-9-000-new-parts-added-in-first-quarter-of-2026–302754079.html

SOURCE Mouser Electronics

Continue Reading

Trending